HR-Related Coronavirus Q&A: Our Answers to Your Questions
Client Alert | 1 min read | 04.21.20
We have drafted an ‘HR-Related Coronavirus Q&A’ in response to recent developments, and we thought that it might be of interest to you. You will find this Q&A here. In it, we take a look at our clients’ most commonly asked questions regarding the impact of the virus.
The questions and answers in this Q&A are of course of a general nature and should not be considered to be comprehensive legal advice on specific questions and/or cases. Do not hesitate to contact our team if you have any specific questions and/or would like any advice with regard to a concrete situation.
You will also find ‘Coronavirus Workplace Guidelines’ for US employers, which include useful tips and recommendations of a general reach as well (EU-based employers may disregard the US-specific guidelines).
Our team will continue to closely monitor developments and keep you posted.
Contacts
Insights
Client Alert | 3 min read | 01.21.26
Atlantic Biologicals Opioid DPA: DOJ Continues Ramp Up of Criminal Corporate Healthcare Enforcement
On January 13, 2026, Miami-based pharmaceutical wholesaler Atlantic Biologicals Corporation entered into a two-year DPA, admitting to conspiracy to distribute and dispense controlled substances, including more than 14 million opioid doses to “pill mill” pharmacies in Texas at a markup. The DOJ and DEA underscored the company’s deliberate evasion of compliance checks and disregard for red flags signaling diversion.
Client Alert | 3 min read | 01.21.26
FedRAMP Proposes Updates to Authorization Process—Six New RFCs Released for Public Comment
Client Alert | 3 min read | 01.20.26
DoW Joins SBA’s Fight Against Alleged Pass-Through Fraud in the 8(a) Program
Client Alert | 3 min read | 01.20.26
Federal Government Challenges Minnesota Law Requiring Affirmative Action in State Government
